Belite Bio Inc ADR

Stock Chart, Company Information, and Scan Results

$166.28(as of Aug 13, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Belite Bio Inc ADR Company Information, Fundamentals, and Technical Indicators

Stock Price$166.28
Ticker SymbolBLTE
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees41
CountyUSA
Market Cap$7,118.3M

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.

Belite Bio Inc ADR In Our Stock Scanner

As of Aug 13, 2026
As of ---
As of ---
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.